[UFTM therapy in patients with unresectable pancreatic cancer].
The therapeutic use of UFTM (UFT plus Mitomycin C) was performed in three patients with unresectable advanced pancreatic carcinoma. According to the criteria of Koyama et al., all patients showed partial response. Thrombocytopenia, (less than 8 x 10(4)/microliter) was observed in one of the three patients treated with UFTM. Nevertheless, in that patient, thrombocytopenia was reversed by stopping Mitomycin C injection and continuous administration of UFT was possible. The survival time in all treated patients tended to the longer: 7.1 months, 13.6 months and 14.1 months. From these results it is suggested that UFTM therapy might offer an alternative treatment for improved survival in patients with unresectable advanced pancreatic carcinoma.
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil